Company / SG&A Expense
BIOMERICA INC SG&A Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$4.6M
FY2024
5-year range
$4.6M / $6.1M
FY2020-FY2024
Trend
-15.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $6M to $5M over the past 2 years.
Based on SEC 10-K filings.
$5M in FY2024 with a 5-year CAGR of +17.9%.
Improved from $6M to $5M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -6.8%
- 5-Year CAGR
- +17.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +17.9%, indicating consistent growth.
- In FY2024, sg&a expense decreased 15.9% year-over-year.
- Peak sg&a expense was recorded in FY2022.
- Lowest sg&a expense in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.26 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $4.6M | -15.9% |
| FY2023 | $5.5M | -9.8% |
| FY2022 | $6.1M | +6.8% |
| FY2021 | $5.7M | +0.5% |
| FY2020 | $5.7M | +180.0% |
| FY2019 | $2.0M | +0.0% |
| FY2018 | $2.0M | +10.2% |
| FY2017 | $1.8M | -0.4% |
| FY2016 | $1.8M | +17.5% |
As of FY2024 · SEC Form 10-K · Last checked Jun 22, 2026